Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera - Scorecard - MDSpire

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

  • By

  • A. Angona

  • B. Cuevas

  • M. Pérez-Encinas

  • F. Ferrer-Marin

  • A. Senín

  • E. Arellano-Rodrigo

  • J. C. Hernández-Boluda

  • M. I. Mata Vázquez

  • G. Caballero-Navarro

  • M. T. Gómez-Casares

  • E. Magro

  • G. Carreño-Tarragona

  • M. A. Cortés-Vázquez

  • R. Pérez López

  • V. García-Gutiérrez

  • M. S. Noya-Pereira

  • J. M. Alonso-Dominguez

  • C. Sierra- Aisa

  • L. Fox

  • C. García Hernández

  • J. M. Guerra

  • E. Cerezo

  • M. Gasior

  • M. Santaliestra

  • I. Díez

  • M. V. Cuevas

  • L. Sanz

  • I. Pastor

  • R. Stuckey

  • P. Vélez

  • C. Auría-Caballero

  • A. Alvarez-Larrán

  • May 7, 2026

  • 0 min

Share

Clinical Scorecard: The Role of Thrombotic Events in Disease Advancement, Cancer Incidence, and Mortality Among Patients with Essential Thrombocythemia and Polycythemia Vera

At a Glance

CategoryDetail
Condition
Key MechanismsThrombotic events (arterial and venous) impact survival, disease progression, and second cancer incidence, with arterial thrombosis showing a more pronounced effect.
Target Population
Care Setting

Key Highlights

  • Thrombotic events significantly lower survival rates in ET and PV patients.
  • Arterial thrombosis (AT) is associated with increased mortality risk.
  • No significant association found between venous thrombosis (VT) and survival; specific study data should be included.
  • JAK2V617F mutation correlates with higher risk of second cancers.
  • AT may indicate a more aggressive disease biology.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular follow-up for thrombotic events and disease progression every 3-6 months.
      • Assess for second cancers in patients with a history of AT.

      Risks

        Patient & Prescribing Data

        Management should prioritize thrombotic event prevention, including options like low-dose aspirin, and monitor for disease progression.

        Clinical Best Practices

        • Implement strategies to reduce thrombotic risk in MPN patients.
        • Educate patients on recognizing symptoms of thrombosis and lifestyle modifications.
        • Utilize genetic testing to inform treatment decisions.

        References

        Original Source(s)

        Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

        • by A. Angona, B. Cuevas, M. Pérez-Encinas, F. Ferrer-Marin, A. Senín, E. Arellano-Rodrigo, J. C. Hernández-Boluda, M. I. Mata Vázquez, G. Caballero-Navarro, M. T. Gómez-Casares, E. Magro, G. Carreño-Tarragona, M. A. Cortés-Vázquez, R. Pérez López, V. García-Gutiérrez, M. S. Noya-Pereira, J. M. Alonso-Dominguez, C. Sierra- Aisa, L. Fox, C. García Hernández, J. M. Guerra, E. Cerezo, M. Gasior, M. Santaliestra, I. Díez, M. V. Cuevas, L. Sanz, I. Pastor, R. Stuckey, P. Vélez, C. Auría-Caballero, A. Alvarez-Larrán

        • May 7, 2026

        Related Content

        Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

        PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

        Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer